- Home
- BCRX
as 07-26-2024 4:00pm EST
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 1.4B | IPO Year: | 1994 |
| Target Price: | $14.67 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.03 - $7.88 | Next Earning Date: | 08-05-2024 |
| Revenue: | $355,395,000 | Revenue Growth: | 22.68% |
| Revenue Growth (this year): | 23.9% | Revenue Growth (next year): | 18.03% |
Stock Insider Trading Activity of BioCryst Pharmaceuticals Inc. (BCRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McKee Amy E | BCRX | Director | Jun 24 '24 | Sell | $6.32 | 8,600 | $54,352.00 | 27,831 | SEC Form 4 |
| SANDERS MACHELLE | BCRX | Director | Jun 17 '24 | Sell | $6.00 | 4,689 | $28,134.00 | 27,742 | SEC Form 4 |
| HEGGIE THERESA | BCRX | Director | Jun 12 '24 | Sell | $6.11 | 6,698 | $40,924.78 | 52,852 | SEC Form 4 |
| LEVIN ALAN G | BCRX | Director | May 30 '24 | Buy | $6.36 | 7,861 | $49,995.96 | 44,951 | SEC Form 4 |
| ASELAGE STEVE | BCRX | Director | May 24 '24 | Buy | $6.40 | 2,500 | $16,000.00 | 2,500 | SEC Form 4 |
| MILANO VINCENT | BCRX | Director | May 20 '24 | Buy | $6.25 | 15,000 | $93,750.00 | 66,997 | SEC Form 4 |
| Hutson Nancy J | BCRX | Director | May 20 '24 | Buy | $6.38 | 5,000 | $31,900.00 | 86,818 | SEC Form 4 |
| Doyle Anthony | BCRX | Chief Financial Officer | May 14 '24 | Buy | $5.57 | 36,300 | $202,191.00 | 266,744 | SEC Form 4 |
| Thackray Helen M. | BCRX | Chief R&D Officer | May 14 '24 | Buy | $5.86 | 30,000 | $175,800.00 | 272,139 | SEC Form 4 |
| Galson Steven K | BCRX | Director | May 13 '24 | Buy | $5.49 | 21,940 | $120,450.60 | 51,551 | SEC Form 4 |
| Stonehouse Jon P | BCRX | President & CEO | May 13 '24 | Buy | $5.55 | 30,000 | $166,500.00 | 1,127,770 | SEC Form 4 |
| Gayer Charles K | BCRX | Chief Commercial Officer | May 13 '24 | Buy | $5.47 | 30,000 | $164,100.00 | 307,533 | SEC Form 4 |
| Barnes Alane P | BCRX | Chief Legal Officer | May 13 '24 | Buy | $5.53 | 5,000 | $27,650.00 | 300,762 | SEC Form 4 |
Latest BioCryst Pharmaceuticals Inc. News
BCRX Breaking Stock News: Dive into BCRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
BioCryst to Report Second Quarter 2024 Financial Results on August 5
Zacks
8 days ago
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
Zacks
8 days ago
Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
Simply Wall St.
10 days ago
BioCryst Pharmaceuticals' (NASDAQ:BCRX) growing losses don't faze investors as the stock spikes 18% this past week
Pharmaceutical Technology
17 days ago
ORLADEYO gains approval in Peru for HAE prevention
MT Newswires
17 days ago
BioCryst Pharmaceuticals Says Orladeyo Approved in Peru
GlobeNewswire
18 days ago
ORLADEYO® (berotralstat) Approved in Peru
GlobeNewswire
25 days ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare BCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCRX BioCryst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.